Evogene (NASDAQ:EVGN) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell?

Shares of Evogene Ltd. (NASDAQ:EVGN) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.26 and traded as low as $1.0950. Evogene shares last traded at $1.11, with a volume of 17,684 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Evogene in a report on Wednesday, October 8th. Alliance Global Partners raised shares of Evogene to a “strong-buy” rating in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.50.

Evogene Stock Up 0.9%

The firm’s fifty day moving average price is $1.21 and its 200-day moving average price is $1.26. The stock has a market cap of $5.96 million, a P/E ratio of -2.22 and a beta of 1.37.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, November 20th. The biotechnology company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.10. The company had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.65 million. Evogene had a negative net margin of 52.33% and a negative return on equity of 75.09%.

Institutional Trading of Evogene

Large investors have recently modified their holdings of the business. Jane Street Group LLC lifted its holdings in Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,387 shares during the period. Citadel Advisors LLC increased its stake in shares of Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 36,206 shares during the period. Finally, Armistice Capital LLC raised its holdings in shares of Evogene by 5.9% during the first quarter. Armistice Capital LLC now owns 316,024 shares of the biotechnology company’s stock valued at $395,000 after acquiring an additional 17,743 shares in the last quarter. 10.40% of the stock is owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.